Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Product Spotlight
Thermo Fisher Scientific/BRAHMS
| Company | Thermo Fisher Scientific/BRAHMS |
|---|---|
| Name of instrument | B⋅R⋅A⋅H⋅M⋅S KRYPTOR compact PLUS |
| City, State | Hennigsdorf, Germany |
| Phone | +49(0)33028830 |
| Website | |
| Type of instrument | immunoassay |
| Operational type/Model type | batch, random access, continuous random access/benchtop |
| List price/First year sold in U.S. | —/2015 |
| Targeted hospital bed size/Targeted | —/daily: 450; monthly: 9, 000; annual: 125, 000 |
| Company manufactures instrument | yes (also sold by distribution partners) |
| Other models in this family of analyzers | B⋅R⋅A⋅H⋅M⋅S KRYPTOR GOLD |
| No. of units in clinical use in U.S./Outside U.S. (countries) | —/> 900 (worldwide) |
| Dimensions (H × W × D)/Instrument footprint | 24 × 29 × 29 in./4.59 sq. ft. |
| Weight empty/Weight fully loaded | 119 lbs./— |
| No. of different measured assays onboard simultaneously | 8 (8 can be run and calibrated at one time) |
| No. of user-definable (open chemistry) channels | — |
| Test throughput per hour/Assay run time | up to 60 (up to 60 tests in throughput)/9–59 min. |
| No. of direct ion-selective electrode channels | — |
| Detection methods | — |
| • Ion-selective electrode | — |
| • Basic metabolic panel | — |
| • Complete metabolic panel | — |
| Typical time delay from ordering stat test until aspiration of sample | — |
| Fully automated microplate immunoassay system | no |
| Methodologies supported | fluorescence, enzyme immunoassay |
| Separation methodologies | none necessary |
| Stat time until completion of a ß-hCG test | 14 min. |
| Stat time until completion of a cTn test | — |
| • Typical time delay from test order to aspiration of sample | — |
| Approximate No. of tests per reagent set/Reagent type | 50–100/self-contained single use |
| Reagents refrigerated onboard/Reagents ready to use | yes (2ϒ–8ϒC)/yes |
| Reagent lot tracking/Reagent inventory | yes/yes |
| Reagent form/Reagents barcoded | liquid chemistry (closed reagent system)/yes |
| Separate reagent pack for each specimen/for each test run | no/no |
| Walkaway capability/Walkaway duration | yes/max. 220 min. (assay dependent) or up to 64 specimens or up to 96 tests |
| Design of sample-handling system | sample cassette placed in sample carousel |
| Uses washable cuvettes/Uses disposable cuvettes | no/no |
| Min.–max. sample volume that can be aspirated at one time | 8–70 µL |
| Min. reaction volume/Min. specimen volume/Min. dead volume | 150 µL/sample tube and assay dependent/150 µL (sample tube dependent) |
| Dedicated pediatric sample cup | yes (dead volume: 75 µL) |
| Primary tube sampling | yes |
| Accommodates most standard tube sizes/Accepts nonstandard tube sizes | yes/yes (11–17 × 60–120 mm) |
| Pierces caps on primary tubes | no |
| Protects against probe collision | no |
| Detects clots/liquid level/short sample | yes/yes/yes |
| Detection or quantitation for hemolysis, icterus, lipemia, clots | detection for hemolysis, icterus, lipemia, clots |
| Dilutes patient samples onboard/Susceptibility to carryover | yes (can be programmed to perform dilutions prior to analysis)/″ 2 parts per million (no contamination) |
| Automatic rerun capability | yes |
| Sample volume can be concentrated to rerun out-of-linear-range low results | yes |
| Analyzer requires dedicated water supply | no |
| Autocalibration/Multipoint calibration supported | yes (calibrants are not stored onboard)/no |
| Typical calibration frequency for ISE/therapeutic drugs/drugs of abuse/general chemistries/immunoassays | —/—/—/—/5–15 days |
| Automatic programmable start/Automatic programmable shutdown | no/no |
| Onboard real-time QC/Onboard software capability to review QC | yes/yes |
| Supports multiple QC lot numbers per analyte | yes |
| Waste management | manually by user, automated collection onboard instrument |
| Sample barcode-reading capability/Autodiscrimination | yes (Interleaved 2 of 5, UPC, Codabar, Code 39, Code 128)/yes |
| Lab can control analyzer from remote computer | no |
| Instrument can diagnose its own malfunctions | yes (operator intervention required to order parts) |
| System malfunctions can be diagnosed via remote monitoring | yes |
| UPS backup power supply | yes |
| Data-management capability/LIS or EHR systems interfaced | onboard/— |
| LIS interface provided/Bidirectional interface capability | yes (additional cost)/yes (broadcast download and host query) |
| Modem servicing provided/Service engineer on-site response time | yes/Mon.–Fri.: 26 hrs. at total breakdown, 72 hrs. at workaround |
| Mean time between failures | — (displays error codes for troubleshooting) |
| Average scheduled maintenance time by lab personnel | daily: 3 min.; weekly: 3 min.; monthly: 5 min. |
| Maintenance records kept onboard for user/vendor | no/no |
| Maintenance training demonstration module onboard | no |
| Training included with purchase/Avg. time for basic user training | yes (1 training slot)/1.5–2 days (at customer site) |
| Advanced operator training/Extra charge for follow-up or advanced training | yes (at vendor site)/yes |
| Warranty provided/Cost of annual service contract (24 h/7 d) | yes (1 year)/contract dependent |
| Distinguishing features (supplied by company) | fully automated random-access immunoanalyzer with unique Nobel Prize–winning TRACE technology; automated timely onboard dilution in less than 5 minutes with integrated self-determining dilution factor; no biotin interferences of the assays |